Clinical Trial Update: Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients [Phase 1, Phase 2]

View source ↗

Summary

Dose-ranging study of PRX-102 in adult Fabry disease patients completed; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fabry Disease

Drugs mentioned

• PRX-102

Snippet

Sponsor: Protalix | Conditions: Fabry Disease | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-01-27